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The short chain fatty acid (SCFA) propionate, produced through fermentation of dietary fibre by the 
gut microbiota, has been shown to alter hepatic metabolic processes that reduce lipid storage. We 
aimed to investigate the impact of raising colonic propionate production on hepatic steatosis in 
adults with non-alcoholic fatty liver disease (NAFLD). Eighteen adults were randomised to receive 
20g/day of an inulin-propionate ester (IPE), designed to deliver propionate to the colon, or an 
inulin-control for 42-days in a parallel design. The change in intrahepatocellular lipid (IHCL) 
following the supplementation period was not different between groups (P=0.082), however IHCL 
significantly increased within the inulin-control group (20.9±2.9 to 26.8±3.9%; P=0.012; n=9), which 
was not observed within the IPE group (22.6±6.9 to 23.5±6.8%; P=0.635; n=9). The predominant 
SCFA from colonic fermentation of inulin is acetate, which in a background of NAFLD and a 
hepatic metabolic profile that promotes fat accretion, may provide surplus lipogenic substrate to the 
liver. The increased colonic delivery of propionate from IPE appears to attenuate this acetate-

















































































Non-alcoholic fatty liver disease (NAFLD), a condition characterized by the accumulation of fat 
within the liver, is regarded as a major risk factor in the development of Type 2 diabetes1. The 
prevalence of NAFLD is strongly associated with obesity1, thus current guidelines for the 
prevention and management of NAFLD are based solely on weight loss through diet and exercise1. 
Whilst lifestyle modifications are successful in reducing body weight in the short-term, numerous 
studies demonstrate that long-term maintenance of weight loss in obese individuals is very poor2. 
Lifestyle modifications alone are therefore unlikely to reduce the growing prevalence of NAFLD and 
there is an urgent need to develop therapeutic interventions that can safely be applied at the 
population level. 
Recent investigations suggest that diet, the gut microbiota and liver fat storage could be linked 
through a mechanism involving short chain fatty acids (SCFA), the major products of dietary fibre 
fermentation in the colon. It has been repeatedly observed that when animals are fed fermentable 
fibre they are protected against steatosis induced by high fat diets3-5. This effect may be due to the 
SCFA propionate, as ~90% of propionate produced in the colon is extracted from the portal vein by 
the liver6, which has been shown to alter hepatic metabolic processes to reduce lipid content7,8.  To 
augment colonic propionate production we have developed an inulin-propionate ester (IPE), 
whereby the SCFA propionate is bound to the dietary fibre inulin, which is released through 
microbial hydrolysis in the colon9. Our recent first-in-human studies provided preliminary evidence 
that supplementing the diet with 10g/day IPE for 24 weeks reduced liver fat content in adults with 
NAFLD9. These volunteers were identified as having NAFLD on the basis of an elevated 
intrahepatocellular lipid (IHCL) content from magnetic resonance imaging. 
The aim of the current study was to develop in vivo proof-of-concept for IPE as a therapeutic to 
reduce hepatic steatosis in volunteers with a histological confirmation of NAFLD, which is 
considered the gold-standard to establish diagnosis. We hypothesised that the addition of 20 g IPE 
to the diet of adults with NAFLD for 42 days would significantly reduce IHCL compared to 20 g of 
an inulin-control.     
 
METHODS 
All volunteers provided informed, written consent prior to the clinical trial which was approved by 
the London Brent Research Ethics Committee (14/LO/0645). The study was carried out in 
accordance with the Declaration of Helsinki and is registered with the ISRCTN registry 
(ISRCTN71814178).A detailed methodology is presented in the Supplementary Material. Men and 
women aged 18-65 years, with a body mass index (BMI) of 20-40 kg/m2 were recruited from liver 
clinics at St Mary’s Hospital, Imperial College Healthcare National Health Service Trust. Potential 
































































volunteers were eligible if they had a confirmation of NAFLD by liver biopsy within the previous five 
years and controlled blood glucose levels (HbA1c <48 mmol/mol). The study was conducted using 
a randomised, double-blind, placebo controlled, parallel design. Subjects received either 20 g/day 
of inulin-control or IPE for 42 days. The 20 g dose of IPE would have provided 14.6 g of inulin (and 
5.4 g bound propionate) to the diet9. Inulin was therefore chosen as a positive control to account 
for any effects that may derive from fermentation of this substrate by the gut microbiota. The 
supplements were provided to volunteers in 10 g ready-to-use sachets and they were instructed to 
mix the contents into their habitual diet twice a day. Participants were required to attend the NIHR 
Imperial Clinical Research Facility pre- (day 0) and post-supplementation (day 42) to determine 
outcome measures.  
 
RESULTS AND DISCUSSION 
Of 20 volunteers that were randomised and enrolled into the study, data were analysed from the 18 
volunteers that completed the supplementation period (Figure S1). The characteristics of these 
volunteers are presented in Table 1 and Table S1. Estimated compliance was similar in the 
supplementation groups (inulin-control: 90±7% vs. IPE: 95±2%; P=0.213). The changes in IHCL 
(Figure 1A-C and Table 1) were unexpected, as we observed an increase in IHCL post-
supplementation in both groups (main effect for time; P=0.020). The change in IHCL was not 
significantly different between supplementation groups (Figure 1A; P=0.082), however, within-
group analysis showed that IHCL was significantly increased within the inulin-control group (Figure 
1B; P=0.012) and not the IPE group (Figure 1C; P=0.635).  Analysis of metabolic and inflammatory 
responses (Figures 1D-I and Tables S2-S4) highlight that the change in insulin resistance (HOMA-
IR) was significantly different between groups (Figure 1D; P=0.046), with a non-significant increase 
in the inulin-control group (Figure 1E; P=0.060) and decrease in the IPE group (Figure 1E; 
P=0.389), respectively. There were no within- or between-group differences in body composition 
(Table 1), self-reported food intake or physical activity following the supplementation period (Table 
S5).  Our hypothesis was that IPE supplementation would decrease IHCL in adults with NAFLD, as 
observed in our previous study9; however, IPE supplementation did not reduce liver fat content. 
The disparate outcome may be explained by methodological differences in IPE dose (10g/day vs. 
20g/day) and exposure (6 weeks vs. 24 weeks) in the two studies. Furthermore, volunteers in the 
present study had a confirmation of NAFLD by liver biopsy, which is considered gold-standard to 
establish diagnosis, and metabolic parameters would indicate these individuals had poorer 
glycaemic control compared to the volunteers from our previous work (fasting glucose: 5.0 mmol/L 
vs. 6.1 mmol/L; HbA1c: 38 mmol/mol vs. 42 mmol/mol).  
 
































































Whilst breath hydrogen, a marker of colonic fermentation, was elevated in both groups post-
supplementation (Table S3), the impact on SCFAs measured in peripheral blood was limited, as 
we observed that IPE supplementation only reduced levels of butyrate in fasting samples 
compared to the inulin-control group (Table S3). The blood samples were collected >12 hours after 
volunteers were requested to ingest their final supplement, which may explain why we were unable 
to detect large differences in circulating SCFAs post-supplementation. Nevertheless, previous 
research using stable isotope methodology has demonstrated that inulin is predominantly 
fermented in the human colon into acetate (82%), with considerably less propionate and butyrate 
produced (6% and 12%, respectively)10.  Dietary supplementation with inulin-type fructans (ITF) 
has generally been associated with positive effects on metabolic health. The evidence for this 
beneficial effect is primarily derived from rodent studies, where dietary supplementation with ITF 
has consistently been shown to prevent the accumulation of liver fat and metabolic dysregulation 
induced by a high fat diet3-5. However, to the best of our knowledge, ITF have not been shown to 
reduce liver fat when added to the diet of rodents with pre-existing steatosis. Studies investigating 
the effect of ITF on metabolic health in humans are equivocal with a recent meta-analysis reporting 
no association between ITF supplementation and fasting glucose and insulin levels11. Fewer 
studies have quantified the impact of ITF supplementation on liver fat content in humans. Our 
previous work demonstrated that 30g/day ITF supplemented into the habitual diet of overweight 
adults with normal glycaemic control had no effect on IHCL12. In contrast, a superior reduction in 
IHCL in adults with pre-diabetes was found  when a weight-loss diet was combined with 30g/day 
ITF supplementation13. The serendipitous observation in the current study is that supplementing 
20g/day inulin into a habitual weight-maintaining diet raises IHCL and further exacerbates glucose 
homeostasis in adults with NAFLD. Taken together, our data suggests that ITF supplementation 
does not have a homogenous impact on hepatic lipid content in humans and its effects may 
depend on the pre-existing metabolic health of the individual and the energy-balance promoted by 
the background diet.  
 
Previous research would suggest that the acetate derived from inulin fermentation would have 
contrasting metabolic fates depending on hepatic lipid metabolism in different physiological 
conditions. For example, it has previously been reported that greater amounts of exogenous 
acetate are used for hepatic de novo lipogenesis (DNL) in obese compared to lean individuals. 
This metabolic response was associated with higher insulin levels in the obese group, which is the 
chief regulator of hepatic DNL14. Previous work has also demonstrated that chronic intragastric 
acetate infusion in rats promotes postprandial hyperinsulineamia and increases liver triglyceride 
content15. The conversion of SCFAs into metabolic intermediates is initially determined by the acyl-
CoA synthetase short-chain family members (ACSS)16. Human hepatocytes express the cytosolic 
isoform ACSS2, which has high specificity for acetate and increases the availability of acetyl-CoA 
for lipid synthesis16. Evidence highlights that, together with higher insulin levels17, humans with 
































































NAFLD have an elevated expression of hepatic genes that favour fat accumulation, with increased 
expression of acetyl-CoA carboxylase (ACC) and fatty acid synthase (FASN), which are key 
enzymes in hepatic DNL18. Consequently, NAFLD patients are reported to have rates of DNL up to 
3-fold higher compared to BMI-matched controls17. The current data suggests that in weight-stable 
individuals with NAFLD, an increased supply of acetate to the liver from the colonic fermentation of 
inulin provides surplus acetyl-CoA for DNL and hepatic lipid accretion. Interestingly, diet-induced 
weight loss in mice has been shown to markedly reduce insulin levels and rates of hepatic DNL19, 
whilst the expression of hepatic DNL-related genes are also reduced by states of chronic negative 
energy balance20. This may explain the disparate effect of inulin supplementation on liver fat 
content in the present study compared to our previous investigation when inulin intervention was 
added to a hypo-caloric diet that achieved a  ~5% reduction in body weight13.   
 
IPE supplementation did not significantly raise IHCL content, as observed within the inulin-control 
group. The contrasting outcome could be due to differences in amounts of acetate derived from 
inulin fermentation throughout the supplementation period, as the inulin-control group were 
provided with a greater amount of inulin compared to IPE (20 g/day vs 14.6 g/day). In vitro faecal 
fermentation profiles have previously demonstrated, however, that comparable quantities of 
acetate are produced from equivalent doses of inulin and IPE9. Interestingly, IPE does substantially 
alter the proportion of SCFAs produced, as the molar ratio of acetate, propionate and butyrate 
changes from 74:16:10 with inulin to 25:69:6 with an equivalent amount of IPE9. It could be 
suggested that the elevated ratio of colonic propionate:acetate promoted by IPE supplementation 
may have prevented the accumulation of liver fat observed in the inulin-control group by impairing 
hepatic acetate metabolism. This proposed mechanism  is concordant with the results from 
Wolever and colleagues who demonstrated using stable isotope technology that propionate inhibits 
incorporation of colonic [1,2-13C] acetate into plasma lipids in humans7. Studies using rat 
hepatocytes have also highlighted that propionate inhibits lipid synthesis when acetate is a major 
source of acetyl-CoA8. Recent evidence has demonstrated a third ACSS isoform, ACSS3, for 
which propionate is the preferred substrate over acetate, and which is highly expressed in the 
mitochondrial matrix of hepatocytes16. ACSS3 converts propionate to propionyl-CoA allowing it to 
enter mitochondrial respiration through succinate and the TCA cycle16. Elevating hepatic 
propionate metabolism would therefore increase competition with acetate for conversion into their 
CoA adducts at tissue level, which may reduce cytosolic acetyl-CoA availability for DNL. This 
potential mechanism is supported by a recent observation that exposing HepG2 cells to elevated 
ratios of propionate:acetate increases the formation of heptadecanoic acid derived from propionyl-
CoA, which inhibits the synthesis of palmitate from acetyl-CoA21.  
 
































































The present study has a number of potential limitations, chiefly, the considerable variability in 
metabolic health of the recruited volunteers. Nevertheless, the individual change in IHCL post-
supplementation were not associated with any baseline metabolic variable (Table S6) and 
significant differences between-groups at baseline were only found in two outcome measures 
(cholesterol and LDL-cholesterol). In addition, the inclusion criteria permitted a histological 
diagnosis of NAFLD within the previous 5 years, thus a volunteer’s histological characterisation 
could have changed in the timeframe between initial diagnosis and recruitment into the study. 
However, all volunteers exhibited a raised IHCL (>5%) when assessed at baseline (Table S1).  
In conclusion, inulin consumed at 20g/day increased IHCL in weight-stable adults with NAFLD, an 
effect not observed with IPE supplementation. We speculate that in the context of NAFLD and a 
hepatic metabolic profile that stimulates DNL, the acetate derived from colonic fermentation of 
inulin could provide additional lipogenic precursor to the liver.  The increased colonic delivery of 
propionate from IPE appears to attenuate this acetate-mediated increase in IHCL, possibly by 
interfering with the availability of acetate-derived acetyl-CoA for DNL. Further work is warranted to 
explore how altering colonic SCFA production profiles modulates the metabolic pathways that 
govern hepatic lipid storage in humans. In particular, future research should determine how the 
hepatic metabolic processing of acetate and propionate changes in different states of energy 
balance and to determine distinctions between NAFLD patients and healthy controls. 
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Table 1. Baseline characteristics of volunteers and changes in intrahepatocellular lipid and body 
composition following 42 days of inulin-control or inulin-propionate ester (IPE) supplementation. 
Data are expressed as mean ± SEM. 
  Inulin-Control IPE Mixed ANOVA 
  (N = 9) (N = 9) Time Group×Time 
Variable Pre  Post P Value Pre  Post P Value P Value P Value 
Sex 
(N) 
   
















   















49 ± 4 
  


































20.9 ± 2.9 26.8 ± 3.9 0.012 22.6 ± 6.9 23.5 ± 6.8 0.635 0.020 0.082 
Weight 
(kg) 
83.3 ± 4.4 83.2 ± 4.0 0.914 93.6 ± 7.6 93.9 ± 7.4 0.556 0.438 0.578 
BMI 
(kg/m2) 
29.5 ± 1.4 29.5 ± 1.4 0.966 31.5 ± 1.9 31.6 ± 1.9 0.377 0.696 0.620 
Fat Mass 
(kg) 
26.8 ± 3.4 27.1 ± 3.3 0.524 35.3 ± 5.2 34.9 ± 5.3 0.485 0.931 0.302 
Fat Free Mass 
(kg) 
56.5 ± 3.7 56.1 ± 3.3 0.631 58.3 ± 5.0 59.1 ± 5.2 0.055+ 0.748 0.341 
+ = non-parametric statistical analysis. Non-alcoholic fatty liver disease (NAFLD), non-alcoholic 
steatohepatitis (NASH), Intrahepatocellular lipid (IHCL), body mass index (BMI). Detailed volunteer 
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Figure 1. Effects of 42 days of inulin-control and inulin-propionate ester (IPE) supplementation on 
liver fat and glucose homeostasis A.-C. Intrahepatocellular lipid (IHCL) D.-F. Homeostatic model 
assessment of insulin resistance (HOMA-IR) and C. Glycosylated haemoglobin (HbA1c) Group data 












































































































































SUPPLEMENTARY MATERIAL  
METHODS 
Potential participants were excluded if they met any of the following criteria:  diagnosis of cirrhosis, 
other clinically significant illness, started new medication or changed the dose of existing 
medication in the preceding 3 months likely to interfere with energy metabolism, a weight loss of 3 
kg or greater in the preceding two months, smoking, substance abuse, psychiatric illness, and any 
abnormalities detected on physical examination, electrocardiography, or screening blood tests 
(measurement of complete blood count, electrolytes and thyroid function). Women were ineligible if 
they were pregnant or breast-feeding. A urinary pregnancy test was conducted at screening and 
before the collection of experimental data at the two study visits. 
A previous investigation found that 20 g/day IPE improved measures of metabolic health (fasting 
insulin and HOMA-IR) in overweight and obese adults at the end of a 42 day intervention 
(unpublished data). Liver fat content was not assessed in this investigation, but it was postulated 
the improvements in glucose homeostasis would be related to reductions in intrahepatocellular lipid 
(IHCL), as observed in previous work1. The same dose (20 g/day) and supplementation period (42 
days) was therefore used in the current study.   
Two strata were defined according to gender and randomisation sequences and allocation was 
conducted via a remote internet-based service (www.sealedenvelope.com). The supplement 
sachets were prepared by DJM and labelled ‘A’ and ‘B’. DJM held the key to the allocations for the 
duration of the trial. Throughout the trial, none of the participants or investigators involved in the 
trial had complete information on the randomisation allocations. 
All subjects were instructed to maintain their usual dietary and activity habits during the study 
period and regular communication between subjects and study investigators encouraged good 
compliance. Subjects returned all their used and unused sachets to estimate compliance. 
The day prior to the study visits, participants were requested to refrain from strenuous exercise and 
alcohol prior to fasting overnight for >12 hours. Participants were asked to eat the same ready-
made or shop-prepared meal the evening before each study visit. Participants were free to choose 
their meal and compliance was assessed by requesting that volunteers bring the outer packaging 
of the meal and the receipt of purchase to the study visit. Participants were requested to ingest 
their final supplement sachet with their evening meal.    
Liver fat, body weight and composition 
Liver fat content was assessed using MRS, as previously described2. Body weight, fat mass (FM) 
and fat free mass (FFM) with bioelectrical impedance (Tanita BC-418MA, Japan). Subjects were 






























































asked to change into lightweight hospital scrubs and to void their bladder before measurements 
were taken.   
Mixed meal test (MMT) 
A cannula was inserted into an antecubital vein and two fasting blood samples were collected >5 
min apart to assess plasma concentrations of glucose and serum concentrations of insulin and 
short chain fatty acids (SCFA). At 0 min, subjects were served a standard liquid meal (Ensure Plus, 
Abbott, UK: 660 kcal; 88.9 g carbohydrate, 21.6 g fat, 27.5 g protein) that was ingested within 10 
min.  Postprandial blood samples were taken at 10, 20, 30, 45, 60, 90, 120 and 180 min and 
collected into sodium fluoride-coated tubes and serum-separating tubes. Plasma glucose was 
measured using an Abbott Architect ci8200 analyser (Abbott Diagnostics, USA). Insulin-like 
immunoreactivity was measured using an ultra-sensitive human insulin radioimmunoassay 
(Millipore, USA). SCFA were measured in fasting and the 60 min samples with the use of an 
Agilent 7000C Triple Quadrupole GC/MS System according to a previously published method 3. 
Fasting breath hydrogen concentrations, a marker of colonic fermentation 4, were measured using 
a handheld breath hydrogen analyser (EC60 Gastrolyser Breath Hydrogen Monitor, Bedfont 
Scientific, Upchurch, Kent, UK). 
 
Cardiovascular disease, diabetes risk factors and inflammatory markers. 
A fasting blood sample was collected and analysed for levels of triglycerides, total cholesterol, low-
density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, glycosylated 
HbA1c, alanine transaminase and C-reactive protein. All analytes were measured by the 
Department of Chemical Pathology, Imperial College Healthcare National Health Service Trust. IL-
6, IL-8, IL-10, IL-12 and IL-17A were measured in fasting serum using the Cytometric Bead Array 
(BD Biosciences, UK), according to the manufacturer’s protocol. IL-17A results are not shown, as 
only two volunteers had detectable values for this analyte. 
Self-reported food intake, physical activity and gastrointestinal adverse events 
Energy and macronutrient intake was recorded with food diaries during the final 3-days of each 
supplementation period (Dietplan 6.0; Forestfield Software Ltd, UK). Physical activity was 
assessed during the final 7 days of each supplementation period using the short self-administered 
format of the International Physical Activity Questionnaire (IPAQ)5. Ratings of gastrointestinal side-
effects were made using 100 mm visual analogue scales (VAS). Subjects were asked to rate the 
occurrence of each side effect with extreme statements anchored at each end of the rating scale (0 
mm Never, 100 mm All the time) 1. 
 
 






























































Calculations and statistical analysis 
Data from our previous study was used to estimate the required sample size 1. A power calculation 
confirmed that 16 participants (8 per group) would be sufficient to detect a mean 8% difference 
between groups in the baseline change in IHCL, with a common standard deviation (SD) of 5% 
(α=0.05, power=0.80). 20 volunteers were recruited to allow an estimated attrition rate of 20%. 
Time course data from the MMT were analysed by calculating areas under the curve (AUC) using 
the trapezoid rule and dividing by 180 to generate a mean postprandial value. Insulin resistance 
was assessed by homeostatic model assessment (HOMA-IR)6.  
Mixed analysis of variance was conducted to assess if the change in outcome measures was 
different over time (pre-supplementation, post-supplementation) between the two supplementation 
groups (inulin-control, IPE). The interaction (Group×Time) and main effect for time are presented. 
Levene’s Test and Box’s Test were performed to confirm homogeneity of variances. Within-group 
differences were compared using paired t tests. Data were checked for normality using the 
Shapiro-Wilk Test. Non-parametric data were log transformed prior to carrying out parametric 
statistical tests. Non-parametric within-group analysis (Wilcoxon signed rank test) was performed 
on data when log transformed values were not normally distributed. Between-group differences at 
baseline were assessed using unpaired t tests. Data were checked for normality using the Shapiro-
Wilk Test. Non-parametric data were log transformed prior to carrying out parametric statistical 
tests. Non-parametric between-group analysis (independent samples Mann-Whitney U Tests) was 
performed on data when log transformed values were not normally distributed.  Correlation 
analysis was performed to assess if the delta change (Δ) in liver fat content was related to baseline 
variables. Pearson correlation coefficients or Spearman’s rank correlation coefficients were 
calculated   All statistical analyses were carried out with SPSS version 23.0 for Windows (SPSS 
Inc, USA). Data are presented as means ± SEM or 95% CI. n = 9 per supplementation group, 
unless otherwise state. Due to difficulties cannulating two volunteers at post-supplementation 
visits, postprandial values from the mixed-meal test MMT were analysed from 16 volunteers (8 per 








































































Figure S1. Recruitment and retention in the study. Inulin-propionate ester (IPE). 































































Figure S2. The effects of 42 days of inulin control and inulin propionate ester (IPE) supplementation 











































































Table S1. Volunteer characteristics. Histological assessment of the liver from biopsy. Intra hepatocellular lipid (IHCL) content, alanine transaminase, HbA1c, 

















Type 2 Diabetes - 
Medication 
Dyslipidaemia -  
Medication 
Hypertension -  
Medication 
1 IC 1 NAFLD None 4 19 61 40 Y- Metformin Y- Statins Y- Bendroflumethiazide 
2 IC 2 NASH Mild 4 24 47 42 N N N 
3 IC 1 NASH None 2 34 123 42 N N N 
4 IC 2 NAFLD Not Specified 5 10 97 40 N Y- Statins N 
5 IC 1 NAFLD None 4 12 36 35 N N Y- Amlodipine 
6 IC 2 NASH Mild 3 29 47 48 Y- Metformin Y- Statins N 
7 IC 1 NAFLD None 4 15 30 37 N N N 
8 IC 1 NAFLD None 2 15 59 41 N Y- Statins N 
9 IC 1 NAFLD None 2 31 33 48 Y- Metformin Y- Statins N 
10 IPE 1 NAFLD None 3 24 30 32 N N N 
11 IPE 1 NAFLD Not Specified 4 25 57 37 N Y- Statins N 
12 IPE 1 NASH Mild 3 23 58 48 Y- Metformin Y- Statins Y- Amlodipine 
13 IPE 1 NAFLD None 2 5 29 35 N N N 
14 IPE 2 NASH None 4 53 122 41 N N N 
15 IPE 1 NAFLD None 3 5 19 42 N Y- Statins Y- Ramipril 
16 IPE 1 NAFLD Not Specified 5 6 11 36 N N N 
17 IPE 1 NAFLD None 3 15 25 46 Y- Metformin Y- Statins N 
18 IPE 2 NASH None 3 46 37 48 N Y- Statins N 
Inulin-control (IC), inulin-propionate ester (IPE), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), Glycosylated haemoglobin (HbA1c). 




































































Table S2. Changes in fasting and postprandial metabolic responses following 42 days of inulin-
control or inulin propionate ester (IPE) supplementation. Data are expressed as mean ± SEM or 95% CI. 
  Inulin-Control IPE Mixed ANOVA 
  (N = 9) (N = 9) Time Group×Time 
Variable Pre  Post P Value Pre  Post P Value P Value P Value 
Fasting Glucose 
(mmol/L) 




8.5 ± 0.7 8.3 ± 0.8 0.610 7.8 ± 0.7 7.9 ± 0.6 0.431 0.897 0.416 
Fasting Insulin 
(µU/mL) 




89.9 ± 12.5 83.67 ± 11.2 0.409 59.4 ± 9.7 59.2 ± 7.7 0.967 0.558 0.494 
HOMA-IR 3.6 ± 0.9 4.5 ± 1.2 0.060 2.6 ± 0.7 2.2 ± 0.6 0.389 0.418 0.046 
HbA1c 
(mmol/mol) 
41.9 ± 3.7 43.5 ± 2.3 0.056 41.5 ± 2.6 41.3 ± 2.5 0.821 0.203 0.113 
Triglycerides 
(mmol/L) 
1.1 ± 0.1 1.9 ± 0.9 0.148+ 1.4 ± 0.3 1.5 ± 0.2 0.842 0.227 0.564 
Cholesterol† 
(mmol/L) 
4.0 ± 0.3 4.0 ± 0.4 0.957 5.4 ± 0.3 5.3 ± 0.4 0.510 0.650 0.597 
LDL Cholesterol† 
(mmol/L) 
2.4 ± 0.2 2.1 ± 0.3 0.303 3.5 ± 0.3 3.4 ± 0.4 0.181 0.143 0.606 
HDL Cholesterol 
(mmol/L) 




59.2± 10.5 67.6 ± 9.4 0.290 43.1 ± 11.2 44.0 ± 11.1 0.718 0.235 0.382 
Breath Hydrogen 
(ppm) 
10.5± 2.9 21.1 ± 5.4 0.014 3.7 ± 0.8 11.4 ± 3.8 0.028 0.001 0.651 
+ = non-parametric statistical analysis. ^ =statistical analysis performed on n=8 each group. † = Significant 
difference between groups at baseline. Homeostatic model assessment of insulin resistance (HOMA-IR), 








































































Table S3. Changes in fasting and postprandial SCFA following 42 days of inulin-control or inulin 
propionate ester (IPE) supplementation. Data are expressed as mean ± SEM or 95% CI. 
  Inulin-Control IPE Mixed ANOVA 
  (N = 9) (N = 9) Time Group×Time 
Variable Pre  Post P Value Pre  Post P Value P Value P Value 
Fasting Acetate 
(µmol/L) 
16.5 ± 2.5 19.7 ± 3.7 0.562 25.4 ± 2.8 35.8 ± 5.5 0.157 0.128 0.409 
Postprandial Acetate^ 
(µmol/L) 
20.4 ± 2.0 24.0 ± 4.1 0.376 25.5 ± 4.3 25.7 ± 4.4 0.955 0.475 0.522 
Fasting Propionate 
(µmol/L) 




2.5 ± 0.3 2.4 ± 0.4 0.640 2.5 ± 0.2 3.2 ± 0.4 0.117 0.262 0.155 
Fasting Butyrate 
(µmol/L) 




2.1± 0.2 2.2 ± 0.2 0.891 1.9 ± 0.2 2.2 ± 0.3 0.548 0.529 0.640 












































































Table S4. Changes in inflammatory markers following 42 days of inulin-control or inulin propionate 
ester (IPE) supplementation. Data are expressed as mean ± SEM or 95% CI. 
  Inulin-Control IPE Mixed ANOVA 
  (N = 9) (N = 9) Time Group×Time 
Variable Pre  Post P Value Pre  Post P Value P Value P Value 
IL-6 
(pg/mL) 
5.4 ± 3.7 3.0 ± 1.2 0.438+ 1.9 ± 0.5 1.7 ± 0.3 0.500+ 0.293 0.541 
IL-8 
(pg/mL) 
7.7 ± 1.6 11.0 ± 4.6 0.610 6.1 ± 1.1 5.8 ± 1.0 0.650 0.942 0.973 
IL-10 
(pg/mL) 
2.0 ± 0.7 3.0 ± 1.2 0.393+ 1.6 ± 0.3 1.4 ± 0.1 0.351+ 0.592 0.269 
IL-12 
(pg/mL) 




2.3 ± 0.7 3.1 ± 1.5 0.672+ 5.8 ± 2.8 5.7 ± 2.9 0.867+ 0.839 0.920 













































































Table S5. Changes in self-reported food intake, physical activity and gastrointestinal side-effects 
following 42 days of inulin-control or propionate ester (IPE) supplementation. Data are expressed as 
mean ± SEM or 95% CI. 
  Inulin-Control IPE Mixed ANOVA 
  (N = 9) (N = 9) Time Group×Time 
Variable Pre  Post P Value Pre  Post P Value P Value P Value 
Energy Intake 
(kcal/day) 
2418 ± 381 2044 ± 235 0.242 2233 ± 254 2268 ± 141 0.878 0.367 0.281 
Carbohydrate 
(g/day) 
275 ± 40 237 ± 25 0.216 248 ± 32 255 ± 24 0.796 0.521 0.185 
Fat 
(g/day) 
112 ± 23 89 ± 13 0.284 93 ± 14 94 ± 8 0.945 0.378 0.338 
Protein 
(g/day) 
95 ± 11 85 ± 9 0.260 101 ± 8 98 ± 5 0.709 0.281 0.589 
Fibre (NSP) 
(g/day) 








25 ± 10 28 ± 9 0.818 9 ± 7 6 ± 2 0.638 0.864 0.909 
Nausea 
(mm) 
11 ± 6 24 ± 10 0.358 11 ± 7 3 ± 1 0.234 0.849 0.154 
Bloating 
(mm) 
22 ± 11 33 ± 12 0.519 9 ± 4 16 ± 5 0.352 0.282 0.949 
Flatulence 
(mm) 
20 ± 10 59 ± 8 0.006 17 ± 8 25 ± 10 0.591 0.020 0.094 
Heartburn 
(mm) 
13 ± 6 5 ± 3 0.292 12 ± 5 3 ± 1 0.145 0.091 0.742 
Belching 
(mm) 
18 ± 10 17 ± 9 0.968 7 ± 4 4 ± 2 0.643 0.870 0.956 
Energy intake was recorded with 3-day food diaries. Physical activity was measured using the short self-
administered format of the International Physical Activity Questionnaire (IPAQ) 
5
. Ratings of gastrointestinal 
side-effects were made using 100 mm visual analogue scales (VAS). Subjects were asked to rate the 
occurrence of each side effect with extreme statements anchored at each end of the rating scale (0 mm 







































































Table S6. Correlations between baseline variables and the delta change (Δ) in IHCL following 42 days 





















IHCL (%) 0.295 0.440 -0.259 0.501 0.138 0.624 
Fasting Glucose (mmol/L) 0.186 0.186 -0.247 0.556 -0.071 0.802 
Postprandial Glucose (mmol/L)^ -0.076 0.858 -0.178 0.674 -0.095 0.736 
Fasting Insulin (µU/mL) -0.291 0.484 0.192 0.650 0.062 0.825 
Postprandial Insulin (µU/mL)^ -0.014 0.974 0.488 0.220 0.075 0.790 
HOMA-IR -0.206 0.625 0.048 0.910 0.050 0.860 
HbA1c (mmol/mol) 0.089 0.819 -0.592 0.093 -0.170 0.545 
Triglycerides (mmol/L) -0.447 0.227 -0.053 0.893 -0.211+ 0.451 
Cholesterol (mmol/L) -0.207 0.593 -0.453 0.221 -0.266 0.338 
LDL Cholesterol (mmol/L) -0.106 0.786 -0.323 0.397 -0.156 0.579 
HDL Cholesterol (mmol/L) -0.216 0.576 -0.276 0.473 -0.185 0.510 
Alanine Transaminase (IU/L) 0.385 0.306 0.134 0.731 0.206 0.462 
Breath Hydrogen (ppm) 0.490 0.218 -0.481 0.227 0.074+ 0.794 
Fasting Acetate (µmol/L) 0.053 0.901 0.128 0.763 0.082+ 0.771 
Postprandial Acetate (µmol/L)^ 0.614 0.105 0.297 0.475 0.303 0.273 
Fasting Propionate (µmol/L) -0.086 0.839 -0.412 0.310 -0.258 0.353 
Postprandial Propionate (µmol/L)^ 0.601 0.115 0.207 0.623 0.416 0.109 
Fasting Butyrate (µmol/L) -0.174 0.728 -0.266 0.524 -0.411 0.128 
Postprandial Butyrate (µmol/L)^ -0.338 0.413 0.642 0.086 -0.041 0.885 
IL-6 (pg/mL) -0.050+ 0.898 -0.365 0.374 -0.279+ 0.315 
IL-8 (pg/mL) 0.007 0.986 -0.193 0.647 -0.161 0.566 
IL-10 (pg/mL) 0.067+ 0.864 -0.578+ 0.133 -0.153+ 0.586 
IL-12 (pg/mL) 0.337 0.318 -0.051 0.904 -0.088+ 0.756 
C Reactive Protein (mg/L) 0.567 0.112 0.233 0.615 0.323 0.022 
Energy Intake (kcal/day) 0.556 0.153 0.037 0.930 0.411 0.128 
Carbohydrate (g/day) 0.512 0.195 0.452+ 0.260 0.439+ 0.101 
Fat (g/day) 0.552 0.156 -0.034 0.937 0.411 0.128 
Protein (g/day) 0.478 0.231 -0.090 0.832 0.232 0.406 
Fibre (NSP) (g/day) 0.243 0.563 0.162 0.701 0.276 0.319 
Total Physical Activity (MET-h/week) -0.405 0.280 -0.076 0.846 -0.428 0.111 
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